Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 842

Results For "ED"

9532 News Found

Covaxin booster dose study shows promising results
News | January 08, 2022

Covaxin booster dose study shows promising results

Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events


Moderna Covid-19 boosters after five-month interval: U.S. FDA
News | January 08, 2022

Moderna Covid-19 boosters after five-month interval: U.S. FDA

Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older


Maharasthra Health Minister inaugurates BSV research centre at Airoli, Maharashtra
Biotech | January 07, 2022

Maharasthra Health Minister inaugurates BSV research centre at Airoli, Maharashtra

The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems


Lupin launches Molnulup to treat Covid-19
News | January 07, 2022

Lupin launches Molnulup to treat Covid-19

The drug is priced at Rs 2000 for a course of 40 tablets


Merck KGaA to acquire biopharma CDMO Exelead for $780 million
Biotech | January 07, 2022

Merck KGaA to acquire biopharma CDMO Exelead for $780 million

The transaction is expected to close in the first quarter of 2022


Lilly and Entos  collaborate for therapies in multiple neurologic indications
Biotech | January 07, 2022

Lilly and Entos collaborate for therapies in multiple neurologic indications

Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly


SyneuRx oral Covid-19 anti-viral drug Pentarlandir shows promise against Delta and Omicron
Biotech | January 07, 2022

SyneuRx oral Covid-19 anti-viral drug Pentarlandir shows promise against Delta and Omicron

Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬


Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours
Biotech | January 07, 2022

Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours

JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6


AstraZeneca and Neurimmune to develop and commercialise NI006
Biotech | January 07, 2022

AstraZeneca and Neurimmune to develop and commercialise NI006

Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition


Barentz appoints Daniel Hitz as CEO, APAC
People | January 07, 2022

Barentz appoints Daniel Hitz as CEO, APAC

Hitz shall assume new role from January 17th, 2022